Pharmaceutical Stock Watch – Why TEVA is One to Watch – Beacon Equity Research (blog)

Pharmaceutical Stock Watch – Why TEVA is One to Watch
Beacon Equity Research (blog)
The benefit offered though QVAR was the lower dose at witch asthma control was achieved. The results were published in the September issue of the Journal of
QVAR(R) Versus Fluticasone in a Real-World Study Highlights the Importance of MarketWatch (press release)

all 12 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *